Elicio Therapeutics Inc. (ELTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $42.46M
Last updated: Nov 17, 2026 at 11:02 AM ET
Elicio Therapeutics Inc. (ELTX) Stock Forecast
Analysts expect Elicio Therapeutics (ELTX) to earn -$1.68 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 3 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.42.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.25, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 3 | 75.0% |
| Hold | 1 | 25.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.68
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.42
- EPS consensus
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.68 | -$1.83 to -$1.60 | 4 |
| Dec 31, 2027 | -$1.42 | -$2.16 to -$1.10 | 4 |
Quarterly Estimates
The EPS consensus falls from -$0.35 for the quarter ending Dec 31, 2026 to -$0.37 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.35 | -$0.41 to -$0.33 | 6 |
| Mar 31, 2027 | -$0.37 | -$0.51 to -$0.29 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.08.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.68 | -$1.89 | -$1.89 | -$1.95 | -$2.08 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.42 | -$1.69 | -$1.69 | -$2.17 | -$2.50 | N/A |
| Quarter ending Mar 31, 2027 | -$0.37 | -$0.44 | -$0.44 | -$0.54 | -$0.63 | N/A |
Frequently Asked Questions About ELTX
What is the ELTX stock forecast?
Consensus analyst estimates put Elicio Therapeutics's EPS at -$1.68 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Buy.
How do analysts rate ELTX stock?
Of 4 analysts covering Elicio Therapeutics, 0 rate it Strong Buy, 3 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ELTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.68, with estimates from -$1.83 to -$1.60 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.42, with estimates from -$2.16 to -$1.10 from 4 analysts.
How many analysts cover ELTX?
4 analysts rate Elicio Therapeutics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ELTX pages: Overview, Earnings, Forecast, Financials, Competitors